WO2007130892A3 - Method for treatment of constipation-predominant irritable bowel syndrome - Google Patents

Method for treatment of constipation-predominant irritable bowel syndrome Download PDF

Info

Publication number
WO2007130892A3
WO2007130892A3 PCT/US2007/067739 US2007067739W WO2007130892A3 WO 2007130892 A3 WO2007130892 A3 WO 2007130892A3 US 2007067739 W US2007067739 W US 2007067739W WO 2007130892 A3 WO2007130892 A3 WO 2007130892A3
Authority
WO
WIPO (PCT)
Prior art keywords
constipation
bowel syndrome
irritable bowel
treatment
ibs
Prior art date
Application number
PCT/US2007/067739
Other languages
French (fr)
Other versions
WO2007130892A2 (en
Inventor
Barry Quart
David Rosenbaum
Original Assignee
Napo Pharmaceuticals Inc
Barry Quart
David Rosenbaum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc, Barry Quart, David Rosenbaum filed Critical Napo Pharmaceuticals Inc
Priority to JP2009509989A priority Critical patent/JP2009535419A/en
Priority to EP07761552A priority patent/EP2015639A4/en
Priority to NZ59567907A priority patent/NZ595679A/en
Priority to MX2008013768A priority patent/MX2008013768A/en
Priority to CA2650022A priority patent/CA2650022C/en
Priority to KR1020137013968A priority patent/KR20130067317A/en
Priority to NZ57204907A priority patent/NZ572049A/en
Priority to AU2007248182A priority patent/AU2007248182B2/en
Publication of WO2007130892A2 publication Critical patent/WO2007130892A2/en
Publication of WO2007130892A3 publication Critical patent/WO2007130892A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Abstract

The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat constipation-predominant irritable bowel syndrome (c-IBS). Treatment of c-IBS includes the treatment of the constipation component of c-IBS as well as the pain and abdominal discomfort associated with c-IBS. In one embodiment, the polymeric proanthocyanidin compound is crofelemer. The present invention in an alternative embodiment also provides methods for treating alternating constipation-predominant/diarrhea-predominant irritable bowel syndrome.
PCT/US2007/067739 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome WO2007130892A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2009509989A JP2009535419A (en) 2006-05-01 2007-04-30 Treatment of constipation-type irritable bowel syndrome
EP07761552A EP2015639A4 (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome
NZ59567907A NZ595679A (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome
MX2008013768A MX2008013768A (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome.
CA2650022A CA2650022C (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome
KR1020137013968A KR20130067317A (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome
NZ57204907A NZ572049A (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome
AU2007248182A AU2007248182B2 (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79707606P 2006-05-01 2006-05-01
US60/797,076 2006-05-01

Publications (2)

Publication Number Publication Date
WO2007130892A2 WO2007130892A2 (en) 2007-11-15
WO2007130892A3 true WO2007130892A3 (en) 2008-10-30

Family

ID=38668465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/067739 WO2007130892A2 (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome

Country Status (19)

Country Link
US (3) US7556831B2 (en)
EP (2) EP2241318B1 (en)
JP (2) JP2009535419A (en)
KR (2) KR20090009292A (en)
AU (1) AU2007248182B2 (en)
CA (1) CA2650022C (en)
CY (1) CY1113723T1 (en)
DK (1) DK2241318T3 (en)
ES (1) ES2401366T3 (en)
HK (1) HK1143541A1 (en)
HR (1) HRP20130203T1 (en)
MX (1) MX2008013768A (en)
NZ (3) NZ595679A (en)
PL (1) PL2241318T3 (en)
PT (1) PT2241318E (en)
RS (1) RS52678B (en)
SG (2) SG195538A1 (en)
SI (1) SI2241318T1 (en)
WO (1) WO2007130892A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
MX2008013768A (en) 2006-05-01 2009-02-03 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome.
WO2007130893A2 (en) * 2006-05-01 2007-11-15 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
JP2012503005A (en) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス Compounds, compositions and methods comprising imidazole derivatives and triazole derivatives.
JP4565219B2 (en) * 2008-12-26 2010-10-20 アサヒビール株式会社 Polyphenol-containing granule or polyphenol-containing chewable tablet and method for producing the same
EP2403938B1 (en) 2009-03-04 2019-12-11 Liveleaf, Inc. Method and material for site activated complexing of biologic molecules
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20120202876A1 (en) * 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
MX348184B (en) * 2010-10-31 2017-06-02 Napo Pharmaceuticals Inc Methods and compositions for treating hiv-associated diarrhea.
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
EP2922557B1 (en) * 2012-11-21 2017-10-04 KBS Research, LLC Herbal supplements and methods of use thereof
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
US9510880B2 (en) 2013-08-13 2016-12-06 Zimmer, Inc. Polyaxial locking mechanism
WO2015184109A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in adult non-human animals
US10282369B2 (en) * 2017-03-08 2019-05-07 Centri Technology, Inc. Fast indexing and searching of encoded documents
JOP20190276A1 (en) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
JOP20190275A1 (en) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc Methods and compositions for treating congenital diarrhea disorder
SG11201913701VA (en) * 2017-07-17 2020-02-27 smartDNA Pty Ltd Method of diagnosing a dysbiosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20050019389A1 (en) * 1996-10-16 2005-01-27 Ps Pharmaceutical, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
US20070104728A1 (en) * 2005-11-10 2007-05-10 Olalde Rangel Jose A Synergistic phytoceutical compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (en) 1983-02-16 1986-10-20 Carl Axel Virdalm MEASURES FOR FIGHTING DISEASE CONDITIONS IN THE FOOD MELTER CONTAINING SHALL OR OUTSIDE OF BEERS OR FRUITS
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
EP0214317B1 (en) 1985-08-30 1988-08-17 Societe Des Produits Nestle S.A. Dietetic product with depurating and antidiarrheal activity and process for its preparation
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (en) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Chestnut tannin extract, procedure for its preparation, and its use
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
WO1998044799A1 (en) 1997-04-10 1998-10-15 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
CN1215561A (en) * 1997-10-27 1999-05-05 邢文海 Health tea
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
CN1159054C (en) 2002-01-22 2004-07-28 随志化 Tongfuzhixie preparation
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7208183B2 (en) 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2007130893A2 (en) 2006-05-01 2007-11-15 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
MX2008013768A (en) 2006-05-01 2009-02-03 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome.
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20120202876A1 (en) 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
MX348184B (en) 2010-10-31 2017-06-02 Napo Pharmaceuticals Inc Methods and compositions for treating hiv-associated diarrhea.
EP2928560A4 (en) 2012-12-07 2016-06-01 Salix Pharmaceuticals Inc Methods and compositions for treating hiv-associated diarrhea

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019389A1 (en) * 1996-10-16 2005-01-27 Ps Pharmaceutical, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20070104728A1 (en) * 2005-11-10 2007-05-10 Olalde Rangel Jose A Synergistic phytoceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FISCHER ET AL.: "A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells", JOURNAL OF ETHNOPHARMACOLOGY, vol. 93, no. 2/3, 2004, pages 351 - 3577, XP008102355 *

Also Published As

Publication number Publication date
US20120128797A1 (en) 2012-05-24
SG195538A1 (en) 2013-12-30
WO2007130892A2 (en) 2007-11-15
JP2009535419A (en) 2009-10-01
HRP20130203T1 (en) 2013-04-30
JP2014058548A (en) 2014-04-03
CA2650022A1 (en) 2007-11-15
KR20090009292A (en) 2009-01-22
CY1113723T1 (en) 2016-06-22
MX2008013768A (en) 2009-02-03
ES2401366T3 (en) 2013-04-19
US20080031983A1 (en) 2008-02-07
NZ609280A (en) 2014-09-26
RS52678B (en) 2013-06-28
US7556831B2 (en) 2009-07-07
KR20130067317A (en) 2013-06-21
US9138450B2 (en) 2015-09-22
EP2241318A1 (en) 2010-10-20
SG161259A1 (en) 2010-05-27
DK2241318T3 (en) 2013-01-21
NZ572049A (en) 2012-08-31
PT2241318E (en) 2013-03-18
PL2241318T3 (en) 2013-05-31
NZ595679A (en) 2013-04-26
US8067041B2 (en) 2011-11-29
AU2007248182B2 (en) 2013-05-23
SI2241318T1 (en) 2013-04-30
EP2015639A2 (en) 2009-01-21
HK1143541A1 (en) 2011-01-07
EP2241318B1 (en) 2012-12-19
EP2015639A4 (en) 2009-11-25
US20090238901A1 (en) 2009-09-24
AU2007248182A1 (en) 2007-11-15
CA2650022C (en) 2017-05-16

Similar Documents

Publication Publication Date Title
WO2007130892A3 (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2007130882A3 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2005107771A3 (en) Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
EA201070740A1 (en) METHOD OF TREATING BONE FRACTURE WITH ANTIBODIES AGAINST SKLEROSTIN
WO2007140312A3 (en) Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2007100675A3 (en) Collagenase for treating cellulite
WO2006086693A3 (en) Medical devices
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2005105107A3 (en) Hormone treatment of multiple sclerosis
WO2007092622A3 (en) Compositions and methods for treating bone
WO2004017948A8 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2007149938A3 (en) Methods for promoting hair growth
WO2006078870A3 (en) Methods for treating adhesive capsulitis
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2007149875A8 (en) Compositions and methods for treating, preventing and/or reversing type-1 diabetes
WO2008057158A3 (en) Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2008066775A3 (en) Compositions and methods to reduce fat and retract skin
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2007100590A3 (en) Methods for treating cellulite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07761552

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007248182

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 572049

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2650022

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009509989

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 8911/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/013768

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007248182

Country of ref document: AU

Date of ref document: 20070430

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007761552

Country of ref document: EP